Arcus Biosciences
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
3928 Point Eden Way, Hayward, California...Phone Number
(510) 694-6200Website
www.arcusbio.comRevenue
$236 MillionStock Symbol
RCUSIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
3
1
1
1
1
About Arcus Biosciences
Founded in 2015, Arcus Biosciences is a highly productive, clinical-stage, global biopharmaceutical company with the goal of developing best-in-class molecules and combination therapies for people with cancer. Our team of scientists, physicians, advisors and other leaders is focused on targeting well-understood biological targets and pathways where there is an opportunity to develop new medicines with a potentially improved safety and efficacy profile.Explore more
Arcus Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Arcus Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Arcus Biosciences launches new products
Website visits: Recent activity has been detected on your website
Click to see if Arcus Biosciences had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Arcus Biosciences
Check out if Arcus Biosciences is spiking on competitors!
Earning: See what the market has to say on Arcus Biosciences recently announced quarterly report
Funding: Get notified immidiatlly once Arcus Biosciences has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Arcus Biosciences has recently received funding, and reach out quickly before it becomes old news!
Arcus Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Arcus Biosciences
Find 3 more new buyers
Compare Similar Companies to Arcus Biosciences
Compare insights from companies similar to Arcus Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Arcus Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Arcus Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Arcus Biosciences.
Arcus Biosciences financials insights
Gather financial insights about Arcus Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Debt
$250M
Arcus Biosciences Tech Stack
A closer look at the technologies used by Arcus Biosciences
Most Recent Scoops
Open Position
Hiring Plans
Arcus Biosciences has more open roles in Medical & Health than it has had at any time in the past 9 months. Areas of expertise include: Drug Discovery, Clinical Trial Management Systems, Oncology, Immunofixation, Clinical Monitoring, Flow Cytometry, and Pharmaceutical Manufacturing.
Hiring Plans
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Earnings, Finance
Arcus Biosciences News & Media
Arcus Biosciences Q4 Earnings Call Highlights
Arcus Biosciences (NYSE:RCUS) used its fourth-quarter and full-year 2025 earnings call to highlight updated clinical data for its lead oncology program, casdatifan, and to outline near-term plans for late-stage development in clear cell renal cell carcinoma (ccRCC). Management also discussed an emerArcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript
Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call February 25, 2026 4:30 PM ESTCompany ParticipantsHolli Kolkey - Vice President of Corporate...Here’s What Analysts Think About Arcus Biosciences (RCUS)
Arcus Biosciences, Inc. (NYSE:RCUS) is one of the best immunotherapy stocks to buy according to hedge funds. On February 12, Arcus Biosciences, Inc. (NYSE:RCUS) was downgraded to Equal Weight from Overweight at Wells Fargo, with the firm bringing the price target on the stock down to $23 from $30. The firm attributed the downgrade to […]Arcus Biosciences, Inc. (RCUS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Arcus Biosciences, Inc. (RCUS) 44th Annual J.P.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Arcus Biosciences
Sign Up For FreeTo access detailed company insights
Founded in 2015, Arcus Biosciences is a highly productive, clinical-stage, global biopharmaceutical company with the goal of developing best-in-class molecules and combination therapies for people with cancer. Our team of scientists, physicians, advisors and other leaders is focused on targeting well-understood biological targets and pathways where... Read More
